The regulatory arbitrage opportunity

The FDA, the EMA, the Japanese PMDA, the UK MHRA, and the regulatory agencies of several other jurisdictions evaluate rare disease therapies on overlapping but distinct timelines, with different evidentiary frameworks and different access pathways. A therapy that receives FDA accelerated approval may take three additional years to clear EMA review. A therapy approved in Japan under expedited orphan-drug pathways may take two more years to reach US approval. A compassionate use program available in one country may have no equivalent in another. The differences produce a structural reality the affected community has known for decades: which country you live in determines when you can access a given therapy.

The patient who can navigate the global regulatory landscape has access to treatments years before the patient who cannot. The historical pattern is that the families who navigate this landscape are wealthy, educated, English-speaking, and connected to academic medical centers in major cities. The infrastructure that supports their navigation is private: medical contacts, advocacy network introductions, regulatory consultants, and the financial means to travel for treatment. The infrastructure is not available to most affected families.

What the data infrastructure changes

A patient-controlled data trust that holds outcome data from patients treated under various jurisdictions' compassionate use, expanded access, and accelerated approval pathways changes the regulatory landscape in two ways.

The first is that outcome data crosses borders even when patients do not. A patient who received an individualized antisense oligonucleotide under expanded access in the US generates data that, with appropriate consent, can be cited in a European marketing authorization application. The data crosses the regulatory border. The infrastructure to make the citation possible is the infrastructure question.

The second is that the regulatory intelligence that has lived in private networks becomes accessible to the affected community at large. Information about which jurisdictions accept which therapies on what pathways, what compassionate use applications have succeeded for which conditions, what timeline a particular regulatory pathway typically follows, has been the proprietary advantage of well-resourced families. The infrastructure that captures this information from patient experience and makes it available to subsequent patients is the infrastructure that democratizes the knowledge.

How the cross-jurisdictional data flow works

The technical implementation depends on the legal status of the patient's consent in the source and destination jurisdictions.

When the patient is treated under compassionate use in country A and the data is captured by the treating physician at the local institution, the data is the institution's data subject to local law. The patient's consent for the data to be used in additional applications, including regulatory applications in country B, is a separate consent that may or may not have been obtained at the time of treatment.

The data trust model captures the consent at the trust level. The patient consents to contribute data to the trust. The consent specifies the categories of use the patient permits, including regulatory submissions in jurisdictions other than where the treatment occurred. The data flows to the trust under the patient's consent, and from the trust to subsequent users under access agreements that respect the patient's consent.

The regulatory acceptance of trust-mediated data is the working question. The FDA's real-world evidence frameworks have evolved to accept patient-attributed data with documented provenance. The EMA's equivalent frameworks have evolved similarly. Both agencies have approved specific products with substantial reliance on real-world evidence. The trust-mediated data flow is consistent with the direction of regulatory evolution; the specific implementation requires close work with the agencies on data quality standards, audit trails, and validation protocols.

The patient-by-patient acceleration

The regulatory acceleration that the data infrastructure enables operates patient-by-patient as much as condition-by-condition.

A patient with a specific ultra-rare variant who receives an individualized therapy under the FDA's Plausible Mechanism Framework generates the safety, mechanism, and efficacy data the next patient with a related variant in the same gene needs. If the next patient is in a jurisdiction with a slower regulatory pathway, the first patient's data accelerates the second patient's access to the equivalent therapy. The data that lives in the trust crosses the border. The patient does not.

The pattern compounds. The third patient builds on the first two. The fourth patient, perhaps in a fourth jurisdiction, builds on the first three. Each treated patient generates data that reduces the regulatory uncertainty for the next patient, in the same jurisdiction or a different one. The acceleration is not theoretical; it is the working dynamic the FDA's Plausible Mechanism Framework explicitly contemplates and that several agencies in other jurisdictions have begun to recognize through their own pathway revisions.

The boundary conditions

The model does not erase regulatory boundaries. Each agency retains authority over what is approved in its jurisdiction. The Plausible Mechanism Framework supports faster development by reducing the per-patient evidentiary burden when mechanism is well-characterized; it does not remove the agency's review function.

The model also requires that the data trust meet the data quality standards each agency requires for evidence to be cited in submissions. A trust that does not meet GDPR requirements cannot have its data cited in EMA submissions. A trust that does not meet 21 CFR Part 11 standards for electronic records cannot have its data cited in FDA submissions. The technical and procedural standards are not insurmountable. They are part of the work of building the trust.

The principal effect of the model is to compress the timeline by which a successful therapy in one jurisdiction becomes accessible in another. The current pattern of two-to-five-year lags between approval in different jurisdictions is partly an artifact of the data not flowing efficiently across the boundary. The data trust improves the data flow. The regulatory pathway, accelerated by the better data, follows.

The patient incentive is direct. Faster access to therapies that work. The infrastructure that delivers it is the infrastructure that holds the data with provenance that regulators accept and consent that the affected community controls.